RPg Family Wealth Advisory’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

RPg Family Wealth Advisory’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.51M	Buy	22,155 +1,046	+5%	+$141K	0.58%	54
2026 Q1	$2.7M	Buy	21,109 +2,304	+12%	+$288K	0.56%	58
2025 Q4	$2.29M	Buy	18,805 +526	+3%	+$60.3K	0.5%	70
2025 Q3	$1.83M	Buy	18,279 +1,621	+10%	+$146K	0.4%	76
2025 Q2	$1.38M	Sell	16,658 -3,355	-17%	-$268K	0.37%	77
2025 Q1	$1.62M	Buy	20,013 +2,109	+12%	+$189K	0.46%	64
2024 Q4	$1.61M	Buy	17,904 +200	+1%	+$19.4K	0.57%	52
2024 Q3	$1.75M	Buy	17,704 +663	+4%	+$65.1K	0.56%	50
2024 Q2	$1.58M	Buy	17,041 +687	+4%	+$61.6K	0.52%	52
2024 Q1	$1.55M	Buy	16,354 +1,816	+12%	+$169K	0.49%	55
2023 Q4	$1.3M	Buy	14,538 +674	+5%	+$50.1K	0.48%	64
2023 Q3	$1.01M	Sell	13,864 -1,820	-12%	-$145K	0.42%	65
2023 Q2	$1.3M	Buy	15,684 +1,065	+7%	+$89.1K	0.52%	57
2023 Q1	$1.11M	Buy	14,619 +1,880	+15%	+$156K	0.61%	50
2022 Q4	$1.06M	Buy	12,739 +5,623	+79%	+$455K	0.72%	41
2022 Q3	$596K	Hold	7,116	–	–	0.31%	59
2022 Q2	$529K	Buy	7,116 +96	+1%	+$7.21K	0.32%	56
2022 Q1	$631K	Buy	7,020 +166	+2%	+$15.3K	0.27%	63
2021 Q4	$767K	Buy	6,854 +197	+3%	+$23.8K	0.3%	54
2021 Q3	$837K	Buy	6,657 +289	+5%	+$37.2K	0.35%	57
2021 Q2	$862K	Buy	+6,368	New	+$837K	0.35%	60
2020 Q4	$1.23M	Hold	8,719	–	–	0.58%	51
2020 Q3	$972K	Buy	8,719 +428	+5%	+$48K	0.51%	53
2020 Q2	$928K	Buy	8,291 +1,832	+28%	+$180K	0.57%	52
2020 Q1	$500K	Buy	6,459 +1,591	+33%	+$141K	0.39%	52
2019 Q4	$463K	Sell	4,868 -2,381	-33%	-$206K	0.27%	69
2019 Q3	$553K	Sell	7,249 -47	-0.6%	-$3.91K	0.33%	60
2019 Q2	$640K	Buy	7,296 +4,682	+179%	+$399K	0.38%	52
2019 Q1	$237K	Buy	+2,614	New	+$222K	0.14%	91
2017 Q3	–	Sell	-178	Closed	-$13.7K	–	317
2017 Q2	$13.7K	Buy	+178	New	+$12.6K	0.01%	274

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

RPg Family Wealth Advisory's XBI Position: Q2 2026 in Review

RPg Family Wealth Advisory increased its State Street SPDR S&P Biotech ETF (XBI) stake by 5% in Q2 2026, buying an estimated $141K and bringing the position to 22,155 shares worth $3.51M. The position accounts for 0.58% of the portfolio, ranked #54.

RPg Family Wealth Advisory first reported a position in XBI in Q2 2017 and has held it in 30 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

RPg Family Wealth Advisory held 22,155 shares of State Street SPDR S&P Biotech ETF worth $3.51M as of Q2 2026.
RPg Family Wealth Advisory bought 1,046 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $141K.
State Street SPDR S&P Biotech ETF made up 0.58% of RPg Family Wealth Advisory's portfolio in Q2 2026, its #54 holding.
RPg Family Wealth Advisory first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and has held it in 30 quarters since.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on RPg Family Wealth Advisory's 13F filing for Q2 2026, filed 4 Aug 2026.